Creating the future of TB and global health.

#DisrupTBtoEndTB

Ending TB is a chance to make history. 

TB is a preventable, treatable, and curable disease, but it is currently the world’s deadliest infectious disease, surpassing COVID-19, HIV, and malaria. According to the WHO’s Global Tuberculosis Report, in 2023 alone, there were 1.25 million deaths from TB and as many as 10.8 million people falling ill with the disease.

While there is a strong economic and social investment case for ending TB, there are several critical and systemic bottlenecks in preventing us from achieving this goal.

Ending TB will require us to:

  1. Transform global health financing;

  2. Build digitally enabled health systems; and

  3. Incubate entrepreneurial solutions.

For example, the future of global health financing will require us to look beyond traditional funding mechanisms and invest in strengthening health insurance programs, leveraging money market mechanisms (i.e., ETFs, mutual funds, etc.) and digital currency platforms, venture capital models, etc.

If we are serious about ending TB, we will need “Re-imagine TB Care”.

Latest & Greatest. 

Country Projects and Partners

Learn about our country projects and partners creating the future of TB and global health

Learn about our future-oriented, virtual platform to modernize how we accelerate the sustainable roll-out of innovations

TB Innovation Sandbox

People-Centered Design tOOLKIT

Learn about our future-oriented, virtual platform to modernize how we accelerate the sustainable roll-out of innovations

Learn about the 400+ innovations that we have identified and mapped to create the future of TB and global health

Innoscan

innovation launch plans (T-minus 5 year)

Learn about our 5-stage strategic roadmap that concretely, practically, and rapidly moves an innovation from pilot to routine use

Stay informed about our latest and greatest developments  

News & Events

Stay updated on our work.

Sign up for updates on the RTC initiative, events, resources, and exciting news in TB innovation.